Investor Presentaiton
Private large
portfolio companies
EXTERNALLY VALUED
ӨӨ
08 RETAIL (PHARMACY) BUSINESS OVERVIEW (CONT'D)
Margin enhancement and strong
growth in para-pharmacy sales
Strong sales in para-pharmacy products of
GEL 57.2 million in 3Q21 (up 30.1% y-o-y),
with 33.5% gross profit margin.
Para-pharmacy sales have the strongest
margins and the share of para-pharmacy
sales in retail revenue reached 35.8% in
3Q21 (33.9% in 2Q21).
CASH FLOW
HIGHLIGHTS
3Q21
9M21
Gross profit margin (%)
GEL million
24.5%
REVENUE
GEORGIA
CAPITAL
AVERAGE BILL SIZE & NUMBER OF BILLS ISSUED
Number of bills issued, million
25.5%
25.5%
25.4% 25.0% 27.4% 25.8% 25.3%
25.3
27.1
Same store growth (%)
28.8
27.6
7.0
7.4
20.4
21.1
NMF
9%
9%
6%
3.6% 14.8% 5.1%
10.6%
800
+18.3%
679.4
614.7
+21.1%
566.1
600
518.6
184.7
478.4
450.3
176.9
150.5
134.5
400
113.9
126.0
193.3
494.7
159.6
200
437.8
336.4
384.1
415.6
48.2
352.4
43.1
116.5
145.1
2017
2018
2019
2020
3Q20
3Q21
9M20
9M21
■Retail
Distribution
Number of pharmacies
countrywide
270
296
309
305
337
EBITDA¹
GEL
18.5
18.5
16.8
16.2
15.6
14.3
13.3
13.4
2017
2018
2019
2020
3Q20
3Q21
9M20
9M21
CUSTOMER INTERACTIONS PER MONTH
Operating cash
flow¹
GEL 26.2m
GEL 39.7m
Operating leverage¹(%)
NMF
7.8%
4.1% -1.4%
1.6%
-5.8% -1.3% -5.8%
c.0.8mln
Change y-o-y
73.8%
-18.0%
EBITDA margin¹ (%)
Loyal customers
8.6%
10.1%
10.6%
10.4%
10.3% 10.6% 10.5%
9.5%
EBITDA to cash
conversion¹
150
127.7%
73.9%
Change y-o-y
36.1ppts
-22.9ppts
Free cash flow¹
GEL million
+7.3%
100
GEL 22.4m
GEL 29.1m
70.4
65.3
+24.7%
52.2
38.9
50
50.1
53.7
16.4
20.5
million
Change y-o-y
64.5%
-34.8%
Georgia Capital PLC | 1. Excluding IFRS16 impact
2.1
2.3
2.4
2.3
2.3
2.5
2.3
2.3
0
2017
2018
2019
2020
3Q20
3Q21
9M20
9M21
2017
2018
2019
2020
3Q20
3Q21
9M20
9M21
57View entire presentation